Updated 2018-11-15

  1. Government of Canada SC. Population estimates on July 1st, by age and sex. Published December 27, 2017. Accessed July 1, 2018.
  2. Ingoe L, Phipps N, Armstrong G, Rajagopal A, Kamali F, Razvi S. Prevalence of treated hypothyroidism in the community: Analysis from general practices in North-East England with implications for the United Kingdom. Clin Endocrinol (Oxf). 87(6):860-864. doi:10.1111/cen.13440
  3. U.S. Department of Health and Human Services. Hypothyroidism (Underactive Thyroid). National Institute of Diabetes and Digestive and Kidney Diseases. Published August 2016. Accessed July 1, 2018.
  4. Demartini B, Ranieri R, Masu A, Selle V, Scarone S, Gambini O. Depressive Symptoms and Major Depressive Disorder in Patients Affected by Subclinical Hypothyroidism: A Cross-sectional Study. J Nerv Ment Dis. 2014;202(8):603–607. doi:10.1097/NMD.0000000000000168
  5. Ahirwar AK, Singh A, Jain A, et al. Raised TSH is associated with endothelial dysfunction in Metabolic Syndrome: A case control study. Romanian J Intern Med Rev Roum Med Interne. 2017;55(4):212-221. doi:10.1515/rjim-2017-0023
  6. Jabbar A, Pingitore A, Pearce SHS, Zaman A. Thyroid hormones and cardiovascular disease. Nat Rev Cardiol. 2017;14(1):39. doi:10.1038/nrcardio.2016.174
  7. Wang J, Zheng X, Sun M, Wang Z. Low serum free thyroxine concentrations associate with increased arterial stiffness in euthyroid subjects: a population-based cross-sectional study. Endocrine. 2015;50(2):465.
  8. Roef GL, Taes YE, Kaufman J-M, Van Daele CM. Thyroid Hormone Levels Within Reference Range Are Associated with Heart Rate, Cardiac Structure, and Function in Middle-Aged Men and Women. Thyroid. 2013;23(8):947-954. doi:10.1089/thy.2012.0471
  9. Giorda CB, Carnà P, Romeo F, Costa G, Tartaglino B, Gnavi R. Prevalence, incidence and associated comorbidities of treated hypothyroidism: an update from a European population. Eur J Endocrinol. 2017;176(5):533-542. doi:10.1530/EJE-16-0559
  10. Tudela M, Casey M, Mcintire D, Cunningham G. Relationship of Subclinical Thyroid Disease to the Incidence of Gestational Diabetes. Obstet Gynecol. 2012;119(5):983–988. doi:10.1097/AOG.0b013e318250aeeb
  11. McGill JB, Riddlesworth TD, Hughes J, DiMeglio LA, Miller KM, Beck RW. Autoimmune diseases in children and adults with type 1 diabetes from the type 1 diabetes exchange clinic registry. In: Diabetologia. Vol 58. ; 2015:S246.
  12. Merrill SJ, Mu Y. Thyroid autoimmunity as a window to autoimmunity: An explanation for sex differences in the prevalence of thyroid autoimmunity. J Theor Biol. 2015;375(C):95–100. doi:10.1016/j.jtbi.2014.12.015
  13. Ministry of Health, Province of British Columbia. Thyroid Function Tests in the Diagnosis and Monitoring of Adults. Published January 1, 2010. Accessed July 2, 2018.
  14. Birk-Urovitz E, Del Guidice ME, Meaney C, Grewal K. Use of thyroid-stimulating hormone tests for identifying primary hypothyroidism in family medicine patients. Can Fam Physician. 2017;63:e389-e394.
  15. Toward Optimized Practice (TOP) Endocrine Working Group. Investigation and management of primary thyroid dysfunction clinical practice guideline. April 2014.
  16. Pantalone KM, Nasr C. Approach to a low TSH level: Patience is a virtue. Cleve Clin J Med. 2010;77(11):803-811. Accessed June 21, 2018.
  17. Canadian Society of Endocrinology and Metabolism, Choosing Wisely Canada, Canadian Medical Association. Five tests and treatments physicians and patients should question in endocrinology. Choosing Wisely Canada. Published June 2017. Accessed July 3, 2018.
  18. Zambrana-García JL, Macías Blanco C, Fernández-Suárez A, et al. Impact of a do-not-do intervention on 12 laboratory measurements. Rev Clin Esp. 2017;217(8):454-459. doi:10.1016/j.rce.2017.07.004
  19. Ruggeri RM, Trimarchi F, Giuffrida G, et al. Autoimmune comorbidities in Hashimoto’s thyroiditis: different patterns of association in adulthood and childhood/adolescence. Eur J Endocrinol. 2017;176(2):133-141. doi:10.1530/EJE-16-0737
  20. Osborne D, Sobczyńska-Malefora A. Autoimmune mechanisms in pernicious anaemia & thyroid disease. Autoimmun Rev. 2015;14(9):763–768. doi:10.1016/j.autrev.2015.04.011
  21. Jara LJ, Vera-Lastra O, Medina G. Atrophic Thyroiditis. In: Diagnostic Criteria in Autoimmune Diseases. Humana Press; 2008:221-225. doi:10.1007/978-1-60327-285-8_42
  22. Japan Thyroid Association. Guidelines. Accessed July 9, 2018.
  23. Kearns JE. Liothyronine (l -triiodothyronine) as a substitute for desiccated thyroid. Q Bull Northwest Univ Med Sch. 1957;31(2):97-98.
  24. Benjamin B, Kerwin JF. 3’-substituted-3, 5-diiodothyronine and salts thereof. September 1964. Accessed July 4, 2018.
  25. Beadles C. Thyroid extract and its effects. The Lancet. 1893;142(3657):839–839. doi:10.1016/S0140-6736(01)96623-1
  26. Tariq A, Wert Y, Cheriyath P, Joshi R. Effects of Long-Term Combination LT4 and LT3 Therapy for Improving Hypothyroidism and Overall Quality of Life. South Med J. 2018;111(6):363-369. doi:10.14423/SMJ.0000000000000823
  27. Hoang TD, Olsen CH, Mai VQ, Clyde PW, Shakir MKM. Desiccated Thyroid Extract Compared With Levothyroxine in the Treatment of Hypothyroidism: A Randomized, Double-Blind, Crossover Study. J Clin Endocrinol Metab. 2013;98(5):1982-1990. doi:10.1210/jc.2012-4107
  28. De P. Use of Dessicated Thyroid Extracts: Time to Beef up the Evidence? Rep Thyroid Res. 2017;1(1):102.
  29. Seaborg E. Combination Treatment for Hypothyroidism. Endocr News. April 2017. Accessed July 8, 2018.
  30. Biondi B, Wartofsky L. Combination Treatment with T4 and T3: Toward Personalized Replacement Therapy in Hypothyroidism? J Clin Endocrinol Metab. 2012;97(7):2256-2271. doi:10.1210/jc.2011-3399
  31. Dayan C, Panicker V. Management of hypothyroidism with combination thyroxine (T4) and triiodothyronine (T3) hormone replacement in clinical practice: a review of suggested guidance. Thyroid Res. 2018;11(1):1. doi:10.1186/s13044-018-0045-x
  32. McAninch EA, Bianco AC. The History and Future of Treatment of Hypothyroidism. Ann Intern Med. 2016;164(1):50-56. doi:10.7326/M15-1799
  33. Rowe M, Hoermann R, Warmingham P. The Diagnosis and Treatment of Hypothyroidism: A Patient‟s Perspective. August 2017.
  34. Shomon M. Natural Desiccated Thyroid Deemed Safe Alternative to Levothyroxine. Verywell Health. Published May 18, 2018. Accessed July 9, 2018.
  35. Bowthorpe JA. Stop the Thyroid Madness: A Patient Revolution Against Decades of Inferior Treatment. 2nd ed. Fredericksburg, TX: Lightning Source Inc; 2012.
  36. Heyman A, Yang J. Stop the Thyroid Madness II: How Thyroid Experts Are Challenging Ineffective Treatments and Improving the Lives of Patients. (Bowthorpe JA, ed.). Lightning Source Inc; 2014.
  37. Hennessey JV, Espaillat R. Current evidence for the treatment of hypothyroidism with levothyroxine/levotriiodothyronine combination therapy versus levothyroxine monotherapy. Int J Clin Pract. 2018;72(2). doi:10.1111/ijcp.13062
  38. Farwell AP. What is the best treatment for hypothyroidism? [Editorial]. Clin Thyroidol Public. 2018;11(4):3.
  39. Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26(1):1-133. doi:10.1089/thy.2015.0020
  40. Drug Shortages Canada. Drug Shortage Report for CYTOMEL. Published 12 2018. Accessed July 4, 2018.
  41. Hawkes N. NHS was overcharged for thyroid drug after company raised price by 6000%. BMJ. 2017;359:j5408. doi:10.1136/bmj.j5408
  42. House of Lords, United Kingdom. Branded Health Service Medicines (Costs) Regulations 2018 – Motion to Regret: 20 Jun 2018: House of Lords debates. TheyWorkForYou. Published June 20, 2018. Accessed July 5, 2018.
  43. Topstad D, Dickinson JA. Thyroid cancer incidence in Canada: a national cancer registry analysis. CMAJ Open. 2017;5(3):E612-E616. doi:10.9778/cmajo.20160162
  44. Fröhlich E, Wahl R. Thyroid Autoimmunity: Role of Anti-thyroid Antibodies in Thyroid and Extra-Thyroidal Diseases. Front Immunol. 2017;8. doi:10.3389/fimmu.2017.00521
  45. Benvenga S, Pintaudi B, Vita R, Di Vieste G, Di Benedetto A. Serum Thyroid Hormone Autoantibodies in Type 1 Diabetes Mellitus. J Clin Endocrinol Metab. 2015;100(5):1870–1878. doi:10.1210/jc.2014-3950
  46. Fontana L, Klein S, Holloszy JO, Premachandra BN. Effect of Long-Term Calorie Restriction with Adequate Protein and Micronutrients on Thyroid Hormones. J Clin Endocrinol Metab. 2006;91(8):3232-3235.
  47. Pałkowska-Goździk E, Lachowicz K, Rosołowska-Huszcz D. Effects of Dietary Protein on Thyroid Axis Activity. Nutrients. 2017;10(1). doi:10.3390/nu10010005
  48. Baghcheghi Y, Salmani H, Beheshti F, Hosseini M. Contribution Of Brain Tissue Oxidative Damage In Hypothyroidism-associated Learning and Memory Impairments.(Review Article). Adv Biomed Res. 2017;6(1):59. doi:10.4103/2277-9175.206699
  49. Hoermann R, Midgley JEM, Larisch R, Dietrich JW. Is pituitary TSH an adequate measure of thyroid hormone-controlled homoeostasis during thyroxine treatment? Eur J Endocrinol. 2013;168(2):271-280. doi:10.1530/EJE-12-0819
  50. Hoermann R, Midgley JEM, Larisch R, Dietrich JW. Relational Stability in the Expression of Normality, Variation, and Control of Thyroid Function. Front Endocrinol. 2016;7. doi:10.3389/fendo.2016.00142
  51. Rudolf Hoermann, John Edward Maurice Midgley, Rolf Larisch, Johannes Wolfgang Christian Dietrich. Advances in applied homeostatic modelling of the relationship between thyrotropin and free thyroxine. PLoS ONE. 2017;12(11):e0187232. doi:10.1371/journal.pone.0187232
  52. Hoermann R, Midgley JEM, Larisch R, Dietrich JW. Homeostatic Control of the Thyroid-Pituitary Axis: Perspectives for Diagnosis and Treatment. Front Endocrinol. 2015;6:177. doi:10.3389/fendo.2015.00177
  53. Norman J. Hypothyroidism: Overview, Causes, and Symptoms. EndocrineWeb. Published February 2, 2018. Accessed July 3, 2018.
  54. Koeppen BM, Stanton BA. Berne & Levy Physiology. 7th ed.. Philadelphia, PA: Elsevier; 2018.
  55. Abdalla SM, Bianco AC. Defending plasma T3 is a biological priority. Clin Endocrinol (Oxf). 2014;81(5):633-641. doi:10.1111/cen.12538
  56. Gnocchi D, Steffensen KR, Bruscalupi G, Parini P. Emerging role of thyroid hormone metabolites. Acta Physiol. 2016;217(3):184–216. doi:10.1111/apha.12648
  57. Garber JR, Cobin RH. Clinical practice guidelines for hypothyroidism in adults: Cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol. 2012;18(6).
  58. Faculty of Medicine, University of Toronto, Soor G. Thyroid disease: Hypo and hyperthyroidism. September 2011. Accessed July 5, 2018.
  59. Chatzitomaris A, Hoermann R, Midgley JE, et al. Thyroid Allostasis–Adaptive Responses of Thyrotropic Feedback Control to Conditions of Strain, Stress, and Developmental Programming. Front Endocrinol. 2017;8. doi:10.3389/fendo.2017.00163
  60. Gullo D, Latina A, Frasca F, Le Moli R, Pellegriti G, Vigneri R. Levothyroxine Monotherapy Cannot Guarantee Euthyroidism in All Athyreotic Patients. PLoS ONE. 2011;6(8). doi:10.1371/journal.pone.0022552
  61. Verburg FA, Mäder U, Grelle I, et al. The thyroid axis “setpoints” are significantly altered after long-term suppressive LT4 therapy. Horm Metab Res Horm Stoffwechselforschung Horm Metab. 2014;46(11):794-799. doi:10.1055/s-0034-1375678
  62. Hoermann R, Midgley JEM, Dietrich JW, Larisch R. Dual control of pituitary thyroid stimulating hormone secretion by thyroxine and triiodothyronine in athyreotic patients. Ther Adv Endocrinol Metab. 2017;8(6):83-95. doi:10.1177/2042018817716401
  63. Hoermann R, Midgley JEM, Larisch R, Dietrich JW. Recent Advances in Thyroid Hormone Regulation: Toward a New Paradigm for Optimal Diagnosis and Treatment. Front Endocrinol. 2017;8. doi:10.3389/fendo.2017.00364
  64. Andersen S, Pedersen KM, Bruun NH, Laurberg P. Narrow Individual Variations in Serum T4 and T3 in Normal Subjects: A Clue to the Understanding of Subclinical Thyroid Disease. J Clin Endocrinol Metab. 2002;87(3):1068-1072. doi:10.1210/jcem.87.3.8165
  65. Accorroni A, Saponaro F, Zucchi R. Tissue thyroid hormones and thyronamines. Heart Fail Rev. 2016;21(4):373-390. doi:10.1007/s10741-016-9553-8
  66. Ito M, Miyauchi A, Kang S, et al. Effect of the presence of remnant thyroid tissue on the serum thyroid hormone balance in thyroidectomized patients. Eur J Endocrinol. 2015;173(3):333–340. doi:10.1530/EJE-15-0138
  67. Hoermann R, Midgley JEM, Larisch R, Dietrich JW. Integration of Peripheral and Glandular Regulation of Triiodothyronine Production by Thyrotropin in Untreated and Thyroxine-Treated Subjects. Horm Metab Res Horm Stoffwechselforschung Horm Metab. 2015;47(9):674-680. doi:10.1055/s-0034-1398616
  68. Ling C, Sun Q, Khang J, et al. Does TSH Reliably Detect Hypothyroid Patients? Ann Thyroid Res. 2018;4(1):122-125. Accessed March 18, 2018.
  69. Biondi B. The Normal TSH Reference Range: What Has Changed in the Last Decade? J Clin Endocrinol Metab. 2013;98(9):3584-3587. doi:10.1210/jc.2013-2760
  70. Gursoy A, Ozduman Cin M, Kamel N, Gullu S. Which thyroid-stimulating hormone level should be sought in hypothyroid patients under L-thyroxine replacement therapy? Int J Clin Pract. 2006;60(6):655-659. doi:10.1111/j.1368-5031.2006.00822.x
  71. Anwer MS, Hashim R, Khan FA, Ijaz A. Frequency of conversion to overt hypothyroidism in patients with and without subclinical hypothyroidism. J Ayub Med Coll Abbottabad JAMC. 2012;24(3-4):166.
  72. Midgley JEM, Hoermann R, Larisch R, Dietrich JW. Physiological states and functional relation between thyrotropin and free thyroxine in thyroid health and disease: in vivo and in silico data suggest a hierarchical model. J Clin Pathol. 2013;66(4):335-342. doi:10.1136/jclinpath-2012-201213
  73. Dentice M, Marsili A, Zavacki A, Larsen PR, Salvatore D. The deiodinases and the control of intracellular thyroid hormone signaling during cellular differentiation. Biochim Biophys Acta BBA – Gen Subj. 2013;1830(7):3937-3945. doi:10.1016/j.bbagen.2012.05.007
  74. Goede SL, Leow MK-S, Smit JWA, Klein HH, Dietrich JW. Hypothalamus–Pituitary–Thyroid Feedback Control: Implications of Mathematical Modeling and Consequences for Thyrotropin (TSH) and Free Thyroxine (FT4) Reference Ranges. Bull Math Biol. 2014;76(6):1270-1287. doi:10.1007/s11538-014-9955-5
  75. Leow MK-S, Goede SL. The homeostatic set point of the hypothalamus-pituitary-thyroid axis – maximum curvature theory for personalized euthyroid targets. Theor Biol Med Model. 2014;11:35. doi:10.1186/1742-4682-11-35
  76. Sjoberg S, Eriksson M, Werner S, Bjellerup P. L-thyroxine treatment in primary hypothyroidism does not increase the content of free triiodothyronine in cerebrospinal fluid: A pilot study. Scand J Clin Lab Invest. 2011;71(1):63.
  77. De Groot LJ. Non-Thyroidal Illness Syndrome is a Manifestation of Hypothalamic-Pituitary Dysfunction, and in View of Current Evidence, Should be Treated with Appropriate Replacement Therapies. Crit Care Clin. 2006;22(1):57–86. doi:10.1016/j.ccc.2005.10.001
  78. Brown SJ, Bremner AP, Hadlow NC, et al. The log TSH–free T4 relationship in a community-based cohort is nonlinear and is influenced by age, smoking and thyroid peroxidase antibody status. Clin Endocrinol (Oxf). 2016;85(5):789-796. doi:10.1111/cen.13107
  79. Fitzgerald SP, Bean NG. The Relationship between Population T4/TSH Set Point Data and T4/TSH Physiology. Journal of Thyroid Research. doi:10.1155/2016/6351473
  80. Fitzgerald SP, Bean NG, Fitzgerald LN. Population data indicate that thyroid regulation is consistent with an equilibrium-point model, but not with a set-point model. Temp Multidiscip Biomed J. 2017;4(2):114-116. doi:10.1080/23328940.2017.1281370
  81. Biondi B, Bartalena L, Cooper DS, Heged s L. The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism. Eur Thyroid J. 2015;4(3):149-163. doi:10.1159/000438750
  82. Janssen R, Muller A, Simonides WS. Cardiac Thyroid Hormone Metabolism and Heart Failure. Eur Thyroid J. 2017;6(3):130-137. doi:10.1159/000469708
  83. Fruehwald-Schultes B, Kerner W, Blank B, Wellhoener P. Excess Triiodothyronine as a Risk Factor of Coronary Events. Arch Intern Med. 2000;160(13):1993-1999. doi:10.1001/archinte.160.13.1993
  84. Danzi S, Klein I. Thyroid disease and the cardiovascular system. Endocrinol Metab Clin North Am. 2014;43(2):517.
  85. Kishi T. Free triiodothyronine, not thyroid stimulating hormone, should be focused on for risk stratification in acute decompensated heart failure. J Cardiol. 2015;66(3):201-202. doi:10.1016/j.jjcc.2015.05.001
  86. Leese GP, Jung RT, Guthrie C, Waugh N. Morbidity in patients on l-thyroxine: a comparison of those with a normal TSH to those with a suppressed TSH. Clin Endocrinol (Oxf). 1992;37(6):500-503. doi:10.1111/j.1365-2265.1992.tb01480.x
  87. Ito M, Miyauchi A, Hisakado M, et al. Biochemical Markers Reflecting Thyroid Function in Athyreotic Patients on Levothyroxine Monotherapy. Thyroid. 2017;27(4):484-490. doi:10.1089/thy.2016.0426
  88. Ito M, Miyauchi A, Morita S, et al. TSH-suppressive doses of levothyroxine are required to achieve preoperative native serum triiodothyronine levels in patients who have undergone total thyroidectomy. Eur J Endocrinol. 2012;167:373-378. doi:DOI: 10.1530/EJE-11-1029
  89. Bertoli A, Valentini A, Cianfarani MA, Gasbarra E, Tarantino U, Federici M. Low FT3: a possible marker of frailty in the elderly. Clin Interv Aging. 2017;12:335-341. doi:10.2147/CIA.S125934
  90. Murphy E, Glüer CC, Reid DM, et al. Thyroid Function within the Upper Normal Range Is Associated with Reduced Bone Mineral Density and an Increased Risk of Nonvertebral Fractures in Healthy Euthyroid Postmenopausal Women. J Clin Endocrinol Metab. 2010;95(7):3173–3181. doi:10.1210/jc.2009-2630
  91. Gao Y-C, Gu Q, Liu Q-P, Ge W-L, Lu H-K. Bone turnover markers in patients with differentiated thyroid carcinoma after levothyroxine withdrawal. Clin Lab. 2010;56(3-4):87-93.
  92. Bomer N, den Hollander W, Ramos YFM, et al. Underlying molecular mechanisms of DIO2 susceptibility in symptomatic osteoarthritis. Ann Rheum Dis. 2015;74(8):1571-1579. doi:10.1136/annrheumdis-2013-204739
  93. Schmid C, Ghirlanda-Keller C, Zwimpfer C, Zoidis E. Triiodothyronine stimulates cystatin C production in bone cells. Biochem Biophys Res Commun. 2012;419(2):425-430. doi:10.1016/j.bbrc.2012.02.040
  94. Tuchendler D, Bolanowski M. The influence of thyroid dysfunction on bone metabolism. Thyroid Res. 2014;7. doi:10.1186/s13044-014-0012-0
  95. Morimura T, Tsunekawa K, Kasahara T, et al. Expression of Type 2 Iodothyronine Deiodinase in Human Osteoblast Is Stimulated by Thyrotropin. Endocrinology. 2005;146(4):2077-2084. doi:10.1210/en.2004-1432
  96. Heemstra KA, van der Deure WM, Peeters RP, Hamdy NA. Thyroid hormone independent associations between serum TSH levels and indicators of bone turnover in cured patients with differentiated thyroid carcinoma. Eur J Endocrinol Eur Fed Endocr Soc. 2008;159(1):69-76.
  97. Kim TH, Joung JY, Kang M, et al. A Modest Protective Effect of Thyrotropin against Bone Loss Is Associated with Plasma Triiodothyronine Levels. PLoS ONE. 2015;10(12):e0145292. Accessed June 10, 2018.
  98. Heemstra KA, Hoftijzer HC, Hamdy NA, et al. Thyroid hormone rather than TSH decreases bone turnover during hypothyroidism in athyroid patients with differentiated thyroid carcinoma. in Clinical aspects of endogenous hypothyroidism and subclinical hyperthyroidism in patients with differentiated thyroid carcinoma [Heemstra, dissertation, chapter 6]. Retrieved from
  99. van Vliet NA, Noordam R, van Klinken JB, et al. Thyroid Stimulating Hormone and Bone Mineral Density: Evidence From a Two-Sample Mendelian Randomization Study and a Candidate Gene Association Study. J Bone Miner Res Off J Am Soc Bone Miner Res. March 2018. doi:10.1002/jbmr.3426
  100. Chaker L, Bianco AC, Jonklaas J, Peeters RP. Hypothyroidism. The Lancet. 2017;390(10101):1550-1562. doi:10.1016/S0140-6736(17)30703-1
  101. Zulewski H, Müller B, Exer P, Miserez AR, Staub JJ. Estimation of tissue hypothyroidism by a new clinical score: evaluation of patients with various grades of hypothyroidism and controls. J Clin Endocrinol Metab. 1997;82(3):771-776. doi:10.1210/jcem.82.3.3810
  102. Staub J-J, Althaus BU, Engler H, et al. Spectrum of subclinical and overt hypothyroidism: Effect on thyrotropin, prolactin, and thyroid reserve, and metabolic impact on peripheral target tissues. Am J Med. 1992;92(6):631–642. doi:10.1016/0002-9343(92)90782-7
  103. Christ-Crain M, Meier C, Huber P, Staub J, Muller B. Effect of L-thyroxine replacement therapy on surrogate markers of skeletal and cardiac function in subclinical hypothyroidism. Endocrinologist. 2004;14(3):161–166. doi:10.1097/01.ten.0000127932.31710.4f
  104. Mucklow JC, Barker DJ. Ankle reflex timing as a screening procedure for the detection of hypothyroidism. J Epidemiol Community Health. 1970;24(1):16-17. doi:10.1136/jech.24.1.16
  105. Ooi TC, Whitlock RML, Frengley PA, Ibbertson HK. Systolic time intervals and ankle reflex time in patients with minimal serum tsh elevation: response to triiodothyronine therapy. Clin Endocrinol (Oxf). 1980;13(6):621–627. doi:10.1111/j.1365-2265.1980.tb03431.x
  106. Shafer B, Nuttall Q. Achilles reflex in thyroid disorders: a 10-year clinical evaluation. Am J Med Sci. 1972;264(4):313–317. doi:10.1097/00000441-197210000-00009
  107. Indra R, Patil S, Joshi R, Pai M, Kalantri S. Accuracy of physical examination in the diagnosis of hypothyroidism: a cross-sectional, double-blind study. J Postgrad Med. 2004;50(1):7–10.
  108. Santi A, Duarte MMMF, Moresco RN, et al. Association between thyroid hormones, lipids and oxidative stress biomarkers in overt hypothyroidism. Clin Chem Lab Med. 2010;48(11):1635-1639. doi:10.1515/CCLM.2010.309
  109. Santi A, Duarte MMMF, de Menezes CC, Loro VL. Association of Lipids with Oxidative Stress Biomarkers in Subclinical Hypothyroidism. Int J Endocrinol. 2012;2012(2012):7. doi:10.1155/2012/856359
  110. Marchiori RC, Pereira LAF, Naujorks AA, et al. Improvement of blood inflammatory marker levels in patients with hypothyroidism under levothyroxine treatment. BMC Endocr Disord. 2015;15. doi:10.1186/s12902-015-0032-3
  111. Harada PHN, Buring JE, Cook NR, Cobble ME, Kulkarni KR, Mora S. Impact of Subclinical Hypothyroidism on Cardiometabolic Biomarkers in Women. J Endocr Soc. 2017;1(2):113-123. doi:10.1210/js.2016-1085
  112. Santi A, Da Cruz IBM, Loro VL, et al. Overt hypothyroidism is associated with blood inflammatory biomarkers dependent of lipid profile. J Appl Biomed. 2016;14(2):119–124. doi:10.1016/j.jab.2015.10.002
  113. Koyuncu CE, Yildirmak ST, Temizel M, et al. Serum resistin and insulin-like growth factor-1 levels in patients with hypothyroidism and hyperthyroidism.(Research Article). J Thyroid Res. January 2013.
  114. Das C, Sahana PK, Sengupta N, Giri D, Roy M, Mukhopadhyay P. Etiology of anemia in primary hypothyroid subjects in a tertiary care center in Eastern India. Indian J Endocrinol Metab. 2012;16(Suppl 2):S361-S363. doi:10.4103/2230-8210.104093
  115. Bashir H, Bhat MH, Farooq R, et al. Comparison of hematological parameters in untreated and treated subclinical hypothyroidism and primary hypothyroidism patients. Med J Islam Repub Iran. 2012;26(4):172-178. Accessed July 2, 2018.
  116. Kalra S, Khandelwal SK, Goyal A. Clinical scoring scales in thyroidology: A compendium. Indian J Endocrinol Metab. 2011;15(Suppl2):S89-S94. doi:10.4103/2230-8210.83332
  117. Stockigt JR. Free thyroid hormone measurement: a critical appraisal. Endocrinol Metab Clin North Am. 2001;30(2):265–289. doi:10.1016/S0889-8529(05)70187-0
  118. Liewendahl K, Helenius T, Lamberg BA, Mähönen H, Wägar G. Free thyroxine, free triiodothyronine, and thyrotropin concentrations in hypothyroid and thyroid carcinoma patients receiving thyroxine therapy. Acta Endocrinol (Copenh). 1987;116(3):418-424.
  119. Davis PJ, Goglia F, Leonard JL. Nongenomic actions of thyroid hormone. Nat Rev Endocrinol. 2016;12(2):111-121. doi:10.1038/nrendo.2015.205
  120. Russell W, Harrison RF, Smith N, et al. Free Triiodothyronine Has a Distinct Circadian Rhythm That Is Delayed but Parallels Thyrotropin Levels. J Clin Endocrinol Metab. 2008;93(6):2300-2306. doi:10.1210/jc.2007-2674
  121. Berberich J, Dietrich JW, Hoermann R, Müller MA. Mathematical Modeling of the Pituitary–Thyroid Feedback Loop: Role of a TSH-T3-Shunt and Sensitivity Analysis. Front Endocrinol. 2018;9. doi:10.3389/fendo.2018.00091
  122. Klein I, Danzi S. Thyroid disease and the heart. Circulation. 2007;116(15):1725.
  123. Daswani R, Shetty R, B. Jayaprakash, N. R. Rau. Association of Thyroid Function with Severity of Coronary Artery Disease in Euthyroid Patients. J Clin Diagn Res JCDR. 2015;9(6):OC10-3. doi:10.7860/JCDR/2015/10908.6059
  124. Vijayvergiya R, Kapoor D, Aggarwal A, Sangwan S, Suri V, Dhawan V. Analysis of traditional and emerging risk factors in premenopausal women with coronary artery disease: A pilot-scale study from North India. Mol Cell Biochem. 2017;432(1-2):67-78. doi:10.1007/s11010-017-2998-9
  125. Kim B-B, Ku Y-H, Han J-Y, Ha J-M. Relation of Triiodothyronine to Subclinical Myocardial Injury in Patients With Chest Pain. Am J Cardiol. 2013;111(8):1087. doi:10.1016/j.amjcard.2012.12.039
  126. Lee Y-M, Ki Y-J, Choi D-H, Kim B-B. Value of Low Triiodothyronine and Subclinical Myocardial Injury for Clinical Outcomes in Chest Pain. Am J Med Sci. 2015;350(5):393.
  127. Patane S, Marte F, Sturiale M. Acute myocardial infarction without significant coronary stenoses associated with endogenous subclinical hyperthyroidism. Int J Cardiol. 2012;156(1):e1-e3. doi:10.1016/j.ijcard.2009.12.014
  128. Panicker V, Saravanan P, Vaidya B, et al. Common variation in the DIO2 gene predicts baseline psychological well-being and response to combination thyroxine plus triiodothyronine therapy in hypothyroid patients. J Clin Endocrinol Metab. 2009;94(5):1623-1629. doi:10.1210/jc.2008-1301
  129. Sesmilo G, Simó O, Choque L, Casamitjana R. Serum free triiodothyronine (T3) to free thyroxine (T4) ratio in treated central hypothyroidism compared with primary hypothyroidism and euthyroidism. Endocrinol Nutr Engl Ed. 2011;58(1):9-15. doi:10.1016/S2173-5093(11)70031-9
  130. Werneck de Castro JP, Fonseca TL, Ueta CB, McAninch EA. Differences in hypothalamic type 2 deiodinase ubiquitination explain localized sensitivity to thyroxine. J Clin Invest. 2015;125(2):769-781. doi:10.1172/JCI77588
  131. Verburg FA, Smit JWA, Grelle I, Visser TJ, Peeters RP, Reiners C. Changes within the thyroid axis after long-term TSH-suppressive levothyroxine therapy. Clin Endocrinol (Oxf). 2012;76:577-581.
  132. Jonklaas J, Davidson B, Bhagat S, Soldin SJ. Triiodothyronine levels in athyreotic individuals during levothyroxine therapy. JAMA. 2008;299(7):769-777. doi:10.1001/jama.299.7.769
  133. Panicker V, Cluett C, Shields B, Murray A. A Common Variation in Deiodinase 1 Gene DIO1 Is Associated with the Relative Levels of Free Thyroxine and Triiodothyronine. J Clin Endocrinol Metab. 2008;93(8):3075-3081. doi:10.1210/jc.2008-0397
  134. Heemstra KA, Hoftijzer H, Deure WM van der, et al. The type 2 deiodinase Thr92Ala polymorphism is associated with increased bone turnover and decreased femoral neck bone mineral density. J Bone Miner Res. 2010;25(6):1385-1391. doi:10.1002/jbmr.27
  135. Gereben B, McAninch EA, Ribeiro MO, Bianco AC. Scope and limitations of iodothyronine deiodinases in hypothyroidism. Nat Rev Endocrinol. 2015;11(11):642-652. doi:10.1038/nrendo.2015.155
  136. Bunevicius A, Leserman J, Girdler SS. Hypothalamic-pituitary-thyroid axis function in women with a menstrually related mood disorder: association with histories of sexual abuse. Psychosom Med. 2012;74(8):810.
  137. Park SY, Park SE, Jung SW, et al. Free triiodothyronine/free thyroxine ratio rather than thyrotropin is more associated with metabolic parameters in healthy euthyroid adult subjects. Clin Endocrinol (Oxf). 2017;87(1):87-96. doi:10.1111/cen.13345
  138. Farasat T, Cheema AM, Khan MN. Hyperinsulinemia and insulin resistance is associated with low T3/T4 ratio in pre diabetic euthyroid pakistani subjects. J Diabetes Complications. 2012;26(6):522. doi:10.1016/j.jdiacomp.2012.05.017
  139. Olivieri O, Girelli D, Stanzial AM, Rossi L. Selenium, zinc, and thyroid hormones in healthy subjects: low T3/T4 ratio in the elderly is related to impaired selenium status. Biol Trace Elem Res. 1996;51(1):31-41. doi:10.1007/BF02790145
  140. van Vliet NA, van der Spoel E, Beekman M, et al. Thyroid status and mortality in nonagenarians from long-lived families and the general population. Aging. 2017;9(10):2223-2234. doi:10.18632/aging.101310
  141. Charalambous M, Hernandez A. Genomic imprinting of the type 3 thyroid hormone deiodinase gene: Regulation and developmental implications. Biochim Biophys Acta. 2013;1830(7):3946-3955. doi:10.1016/j.bbagen.2012.03.015
  142. Rhee CM, Brent GA, Kovesdy CP, et al. Thyroid functional disease: an under-recognized cardiovascular risk factor in kidney disease patients. Nephrol Dial Transplant. 2015;30(5):724-737. doi:10.1093/ndt/gfu024
  143. Peeters RP, Wouters PJ, van Toor H, Kaptein E, Visser TJ, Van den Berghe G. Serum 3,3′,5′-Triiodothyronine (rT3) and 3,5,3′-Triiodothyronine/rT3 Are Prognostic Markers in Critically Ill Patients and Are Associated with Postmortem Tissue Deiodinase Activities. J Clin Endocrinol Metab. 2005;90(8):4559-4565. doi:10.1210/jc.2005-0535
  144. Wadwekar D, Kabadi UM. Thyroid hormone indices during illness in six hypothyroid subjects rendered euthyroid with levothyroxine therapy. Exp Clin Endocrinol Diabetes Off J Ger Soc Endocrinol Ger Diabetes Assoc. 2004;112(7):373-377. doi:10.1055/s-2004-821012
  145. Ruiz-Núñez B, Tarasse R, Vogelaar EF, Dijck-Brouwer J, A D, Muskiet FAJ. Higher Prevalence of “Low T3 Syndrome” in Patients With Chronic Fatigue Syndrome: A Case–Control Study. Front Endocrinol. 2018;9. doi:10.3389/fendo.2018.00097
  146. Somppi TL. Non-Thyroidal Illness Syndrome in Patients Exposed to Indoor Air Dampness Microbiota Treated Successfully with Triiodothyronine. Front Immunol. 2017;8. doi:10.3389/fimmu.2017.00919
  147. Petrone A, Mormile F, Bruni G, Quartieri M, Bonsignore MR, Marrone O. Abnormal thyroid hormones and non-thyroidal illness syndrome in obstructive sleep apnea, and effects of CPAP treatment. Sleep Med. 2016;23:21-25. doi:10.1016/j.sleep.2016.07.002
  148. Bianco AC. Minireview: cracking the metabolic code for thyroid hormone signaling. Endocrinology. 2011;152(9):3306-3311. doi:10.1210/en.2011-1104
  149. Xue J, Zhang L, Qin Z, et al. No obvious sympathetic excitation after massive levothyroxine overdose. Medicine (Baltimore). 2018;97(23). doi:10.1097/MD.0000000000010909
  150. Stop The Thyroid Madness. Dosing with T3-only (or with low-dose NDT, or the combination of T4/T3). Stop The Thyroid Madness. Accessed July 9, 2018.
  151. Peeters P, Van Der Geyten J, Wouters M, et al. Tissue Thyroid Hormone Levels in Critical Illness. J Clin Endocrinol Metab. 2005;90(12):6498–6507. doi:10.1210/jc.2005-1013
  152. Amin A, Chitsazan M, Taghavi S, Ardeshiri M. Effects of triiodothyronine replacement therapy in patients with chronic stable heart failure and low‐triiodothyronine syndrome: a randomized, double‐blind, placebo‐controlled study. ESC Heart Fail. 2015;2(1):5-11. doi:10.1002/ehf2.12025
  153. Holmager P, Schmidt U, Mark P, Andersen U. Long-term L-Triiodothyronine (T3) treatment in stable systolic heart failure patients: a randomised, double-blind, cross-over, placebo-controlled intervention study. Clin Endocrinol (Oxf). 2015;83(6):931.
  154. Brent GA, Hershman JM. Thyroxine therapy in patients with severe nonthyroidal illnesses and low serum thyroxine concentration. J Clin Endocrinol Metab. 1986;63(1):1-8. doi:10.1210/jcem-63-1-1
  155. Adler SM, Wartofsky L. The Nonthyroidal Illness Syndrome. Endocrinol Metab Clin North Am. 2007;36(3):657–672. doi:10.1016/j.ecl.2007.04.007
  156. LeBoff MS, Kaplan MM, Silva JE, Larsen PR. Bioavailability of thyroid hormones from oral replacement preparations. Metabolism. 1982;31(9):900-905.
  157. Hansen MP, Matheis N, Kahaly GJ. Type 1 diabetes and polyglandular autoimmune syndrome: A review. World J Diabetes. 2015;6(1):67-79. doi:10.4239/wjd.v6.i1.67
  158. Shaikh SB, Haji IM, Doddamani P, Rahman M. A Study of Autoimmune Polyglandular Syndrome (APS) in Patients with Type1 Diabetes Mellitus (T1DM) Followed Up at a Teritiary Care Hospital. J Clin Diagn Res JCDR. 2014;8(2):70-72. doi:10.7860/JCDR/2014/7013.4011
  159. Cellini M, Santaguida MG, Virili C, et al. Hashimoto’s Thyroiditis and Autoimmune Gastritis. Front Endocrinol. 2017;8. doi:10.3389/fendo.2017.00092
  160. Twito O, Shapiro Y, Golan-Cohen A, Dickstein Y, Ness-Abramof R, Shapiro M. Anti-thyroid antibodies, parietal cell antibodies and tissue transglutaminase antibodies in patients with autoimmune thyroid disease. Arch Med Sci AMS. 2018;14(3):516-520. doi:10.5114/aoms.2016.58743
  161. Cho BY, Shong YK, Lee HK, Koh CS. Role of Blocking TSH Receptor Antibodies on the Development of Hypothyroidism and Thyroid Atrophy in Primary Myxedema. Korean J Intern Med. 1989;4(2):108.
  162. Diana T, Krause J, Olivo PD, et al. Prevalence and clinical relevance of thyroid stimulating hormone receptor-blocking antibodies in autoimmune thyroid disease. Clin Exp Immunol. 2017;189(3):304-309. doi:10.1111/cei.12980
  163. Orgiazzi J. Anti-TSH Receptor Antibodies in Clinical Practice. Endocrinol Metab Clin North Am. 2000;29(2):339-355. doi:10.1016/S0889-8529(05)70135-3
  164. Taguchi T, Iwasaki Y, Asaba K, Takao T. Myxedema coma and cardiac ischemia in relation to thyroid hormone replacement therapy in a 38-year-old Japanese woman. Clin Ther. 2007;29(12):2710-2714. doi:10.1016/j.clinthera.2007.12.025
  165. Carlé A, Pedersen IB, Knudsen N, et al. Thyroid Volume in Hypothyroidism due to Autoimmune Disease Follows a Unimodal Distribution: Evidence against Primary Thyroid Atrophy and Autoimmune Thyroiditis Being Distinct Diseases. J Clin Endocrinol Metab. 2009;94(3):833-839. doi:10.1210/jc.2008-1370
  166. McLachlan SM, Rapoport B. Thyrotropin-Blocking Autoantibodies and Thyroid-Stimulating Autoantibodies: Potential Mechanisms Involved in the Pendulum Swinging from Hypothyroidism to Hyperthyroidism or Vice Versa. Thyroid. 2013;23(1):14-24. doi:10.1089/thy.2012.0374
  167. Takasu N, Matsushita M. Changes of TSH-Stimulation Blocking Antibody (TSBAb) and Thyroid Stimulating Antibody (TSAb) Over 10 Years in 34 TSBAb-Positive Patients with Hypothyroidism and in 98 TSAb-Positive Graves’ Patients with Hyperthyroidism: Reevaluation of TSBAb and TSAb in TSH-Receptor-Antibody (TRAb)-Positive Patients. J Thyroid Res. 2012;2012:182176. doi:10.1155/2012/182176
  168. Maynard S, Miller RG. Atrophic Thyroiditis. Clinical Advisor. Published December 20, 2016. Accessed September 17, 2017.
  169. Hong HS, Lee EH, Jeong SH, Park J, Lee H. Ultrasonography of Various Thyroid Diseases in Children and Adolescents: A Pictorial Essay. Korean J Radiol. 2015;16(2):419-429. doi:10.3348/kjr.2015.16.2.419
  170. Chaudhary V, Bano S. Thyroid ultrasound. Indian J Endocrinol Metab. 2013;17(2):219-227. doi:10.4103/2230-8210.109667
  171. Duran AO, Anil C, Gursoy A, Nar A. Thyroid volume in patients with glucose metabolism disorders. Arq Bras Endocrinol Metabol. 2014;58(8):824-827. doi:10.1590/0004-2730000003418
  172. Cakir E, Sahin M, Topaloglu O, Colak NB. The relationship between LH and thyroid volume in patients with PCOS. J Ovarian Res. 2012;5(1):43.
  173. Duran AO, Anil C, Gursoy A, Nar A. The relationship between thyroid volume and malignant thyroid disease. Med Oncol. 2014;31(1):1-4. doi:10.1007/s12032-013-0814-2
  174. Jonklaas J, Burman KD, Wang H, Latham KR. Single Dose T3 Administration: Kinetics and Effects on Biochemical and Physiologic Parameters. Ther Drug Monit. 2015;37(1):110-118. doi:10.1097/FTD.0000000000000113
  175. Fekete C, Lechan RM. Central Regulation of Hypothalamic-Pituitary-Thyroid Axis Under Physiological and Pathophysiological Conditions. Endocr Rev. 2014;35(2):159-194. doi:10.1210/er.2013-1087
  176. Klein I, Danzi S. Thyroid Disease and the Heart. Curr Probl Cardiol. 2016;41(2):65.
  177. Koehler VF, Reincke M, Spitzweg C. Hypothyroidism-when and how to treat? Internist. 2018;38(3):1-7. doi:10.1007/s00108-018-0438-x
  178. Biondi B, Wartofsky L. Treatment with thyroid hormone. Endocr Rev. 2014;35(3):433.
  179. Gustafson C. Antonio C. Bianco, MD, PhD: Is T4 Enough for Patients With Hypothyroid Dysfunction? Integr Med. 2014;13(3):20.
  180. Carlé A, Faber J, Steffensen R, Laurberg P, Nygaard B. Hypothyroid Patients Encoding Combined MCT10 and DIO2 Gene Polymorphisms May Prefer L-T3 + L-T4 Combination Treatment – Data Using a Blind, Randomized, Clinical Study. Eur Thyroid J. 2017;6(3):143-151. doi:10.1159/000469709
  181. Min W, Liu C, Yang Y, et al. Alterations in hypothalamic–pituitary–adrenal/thyroid (HPA/HPT) axes correlated with the clinical manifestations of depression. Prog Neuropsychopharmacol Biol Psychiatry. 2012;39(1):206–211. doi:10.1016/j.pnpbp.2012.06.017
  182. Sawin CT, Hershman JM, Chopra IJ. The comparative effect of T4 and T3 on the TSH response to TRH in young adult men. J Clin Endocrinol Metab. 1977;44(2):273-278. doi:10.1210/jcem-44-2-273
  183. Stop The Thyroid Madness. TSH – Why It’s Useless. Stop The Thyroid Madness. Accessed July 5, 2018.
  184. Parmentier T, Sienaert P. The use of triiodothyronine (T3) in the treatment of bipolar depression: A review of the literature. J Affect Disord. 2018;229:410-414. doi:10.1016/j.jad.2017.12.071
  185. CHERNOW B, BURMAN KD, JOHNSON DL, MCGUIRE RA. T3 may be a better agent than T4 in the critically ill hypothyroid patient. Crit Care Med. 1983;11(2):99-104. doi:10.1097/00003246-198302000-00009
  186. D’Intino G, Lorenzini L, Fernandez M, Taglioni A. Triiodothyronine Administration Ameliorates the Demyelination/Remyelination Ratio in a Non‐Human Primate Model of Multiple Sclerosis by Correcting Tissue Hypothyroidism. J Neuroendocrinol. 2011;23(9):778-790. doi:10.1111/j.1365-2826.2011.02181.x
  187. Cooper-Kazaz R, Lerer B. Efficacy and safety of triiodothyronine supplementation in patients with major depressive disorder treated with specific serotonin reuptake inhibitors. Int J Neuropsychopharmacol. 2008;11(5):685-699. doi:10.1017/S1461145707008206
  188. Garlow SJ, Dunlop BW, Ninan PT, Nemeroff CB. The combination of triiodothyronine (T3) and sertraline is not superior to sertraline monotherapy in the treatment of major depressive disorder. J Psychiatr Res. 2012;46(11):1406-1413. doi:10.1016/j.jpsychires.2012.08.009
  189. Iosifescu DV |Bolo. Brain Bioenergetics and Response to Triiodothyronine Augmentation in Major Depressive Disorder. Biol Psychiatry. 2008;63(12):1127-1134. doi:10.1016/j.biopsych.2007.11.020
  190. Kaptein EM, Sanchez A, Beale E, Chan LS. Clinical review: Thyroid hormone therapy for postoperative nonthyroidal illnesses: a systematic review and synthesis. J Clin Endocrinol Metab. 2010;95(10):4526-4534. doi:10.1210/jc.2010-1052
  191. Pingitore A, Galli E, Barison A, Iervasi A. Acute effects of triiodothyronine (T3) replacement therapy in patients with chronic heart failure and low-T3 syndrome: a randomized, placebo-controlled study. J Clin Endocrinol Metab. 2008;93(4):1351.
  192. Iliopoulou I, Mourouzis I, Lambrou GI, Iliopoulou D, Koutsouris D-D, Pantos C. Time‑dependent and independent effects of thyroid hormone administration following myocardial infarction in rats. Mol Med Rep. 2018;18(1):864-876. doi:10.3892/mmr.2018.9008
  193. Wall CR. Myxedema Coma: Diagnosis and Treatment. Am Fam Physician. 2000;62(11):2485-2490. Accessed July 6, 2018.
  194. Hylander B, Rosenqvist U. Treatment of myxoedema coma–factors associated with fatal outcome. Acta Endocrinol (Copenh). 1985;108(1):65-71.
  195. Spyridoulias A, Riaz MS. Myxoedema coma in the setting of hyperglycaemic hyperosmolar state. BMJ Case Rep. 2016;2016. doi:10.1136/bcr-2015-213411
  196. Robinson P. Recovering with T3: My Journey from Hypothyroidism to Good Health Using Hte T3 Hormone. 2nd Revised ed. Elephant in the Room Books; 2013.
  197. Robinson P. The Ct3M Handbook: Recovering Adrenal Health Using the Circadian T3 Method. Elephant in the Room Books; 2013.
  198. Ellyin F, Fuh CY, Singh SP, Kumar Y. Hypothyroidism with angina pectoris. A clinical dilemma. Postgrad Med. 1986;79(7):93-98.
  199. Dutta P, Bhansali A, Masoodi SR, Bhadada S, Sharma N, Rajput R. Predictors of outcome in myxoedema coma: a study from a tertiary care centre. Crit Care. 2008;12(1):R1. doi:10.1186/cc6211
  200. Skinner GRB. High dosage thyroid replacement should be considered in “refractory” hypothyroidism [In response to article ‘Thyroid function tests and hypothyroidism: Measurement of serum TSH alone may not always reflect thyroid status’]. BMJ. 2003;326(7384):295-296. doi:10.1136/bmj.326.7384.295


Back to Campaign Statement index